



Attorney's Docket No. 9233-8DV1

PATENT

RECEIVED
NOV 08 2002
TECH CENTER 1600
1627
#G1098
26203

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Ekwuribe et al.

Serial No.: 09/429,798

Filed: October 29, 1999

For: *BLOOD-BRAIN BARRIER THERAPEUTICS*

Group Art Unit: 1627

Examiner: T. Prasthoferi


Date: October 31, 2002

Commissioner for Patents
Washington, DC 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

Attached is a form PTO-1449, together with a copy of the identified document(s). This Information Disclosure Statement is submitted in accordance with 37 C.F.R. § 1.97(b), within three months of the filing date of the above-referenced application or before the mailing of a first Office Action on the merits, whichever event occurs last. Accordingly, no fee is required. The Commissioner is authorized to charge any additional fee, or credit any refund, to our Deposit Account No. 50-0220.

Respectfully submitted,

J. Michael Strickland
Registration No. 47,115

USPTO Customer No.:



20792

PATENT TRADEMARK OFFICE

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on October 31, 2002.

Monica L. Croom
Monica L. Croom

EXAMINER
EXAMINER

DATE CONSIDERED
Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

DATE CONSIDERED